caa a22 4500 477071066 CHVBK 20180405111425.0 cr unu---uuuuu 170330e19960801xx s 000 0 eng 10.1007/BF01691147 doi (NATIONALLICENCE)springer-10.1007/BF01691147 Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients [Elektronische Daten] [G. Bodey, D. Abi-Said, K. Rolston, I. Raad, E. Whimbey] The purpose of this prospective randomized study was to compare the efficacy and safety of imipenem and cefoperazone-sulbactam combined with vancomycin for the treatment of fever in neutropenic cancer patients. Patients were assigned to either imipenem 500 mg/m2 (500 mg for bone marrow transplant recipients) every 6 h or cefoperazone (2 g)-sulbactam (1 g) every 8 h. All patients received vancomycin 1 g every 12 h. A total of 457 febrile or infectious episodes occurring in 407 patients were entered in the study. The response rate was 73% for imipenem plus vancomycin and 74% for cefoperazone-sulbactam plus vancomycin among the 369 episodes that could be evaluated. Response rates were comparable for the two regimens with regard to infecting organism, administration of antimicrobial prophylaxis, and neutrophil count and trend. The frequency of side-effects was significantly higher for imipenem plus vancomycin (11 % vs. 5%, p = 0.02), due to therapy-associated nausea and vomiting (5.3% vs. 0%, p = 0.0004). The overall frequency of superinfections was similar with both regimens, butClostridium difficile colitis occurred significantly more often in patients receiving imipenem plus vancomycin (5 vs. 0, p = 0.02). In this study cefoperazone-sulbactam plus vancomycin was an effective alternative to imipenem plus vancomycin for initial therapy of fever in neutropenic patients. Springer-Verlag, 1996 Bodey G. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut Abi-Said D. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut Rolston K. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut Raad I. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut Whimbey E. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/8(1996-08-01), 625-634 0934-9723 15:8<625 1996 15 10096 https://doi.org/10.1007/BF01691147 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01691147 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bodey G. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Abi-Said D. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Rolston K. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Raad I. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Whimbey E. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/8(1996-08-01), 625-634 0934-9723 15:8<625 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer